Eric Langer Joins Editorial Advisory Board of BioPharm International
Eric S. Langer, president and managing partner at BioPlan Associates, Inc. (Rockville, MD) has joined the Editorial Advisory Board of BioPharm International.
Eric S. Langer, president and managing partner at BioPlan Associates, Inc. (Rockville, MD) has joined the Editorial Advisory Board of BioPharm International.
Langer has more than 20 years’ experience in biotechnology and the life sciences, focused on international marketing management, market assessment, and publishing. He has published, edited, and authored numerous books, reports, and major studies about the industry, on topics such as: advances in biopharmaceutical technology in China, advances in large-scale biopharmaceutical manufacturing, biopharmaceuticals in the US market, cell culture, media, DNA/PCR purification, and many others. Langer teaches at Johns Hopkins University and American University and has developed numerous courses, classes, and seminar programs, including Marketing in a Regulated Environment, Marketing Technical Products, and TechniManagement. In 1989, Langer co-founded BioPlan Associates, Inc. a biotechnology and life sciences marketing company.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
